First-in-human trial of Dz13 for nodular basal-cell carcinoma
Mené sur 9 patients atteints d'un carcinome basocellulaire nodulaire, cet essai australien de phase I évalue la faisabilité et la toxicité d'une injection intratumorale d'une enzyme ADN, Dz13
Nucleic-acid-based drugs 1 are a novel class of drugs with great therapeutic potential. Among these are DNAzymes, 2 which contain short stretches of single-stranded DNA molecules synthesised in vitro. 3 A DNAzyme can recognise through Watson-Crick basepairing a specific messenger RNA (mRNA) sequence and induce cleavage between a purine and a pyrimidine residue. Upon cleavage, the target mRNA undergoes accelerated degradation, which leads to a reduction in the concentration of the encoded protein and...
The Lancet , commentaire, 2012